ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series o...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/b881dfb55ce4481c96fc619a4d0cc19a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:b881dfb55ce4481c96fc619a4d0cc19a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:b881dfb55ce4481c96fc619a4d0cc19a2021-11-18T07:47:14ZARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.1932-620310.1371/journal.pone.0062483https://doaj.org/article/b881dfb55ce4481c96fc619a4d0cc19a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23650517/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series of patients with UBC. In the first tumor series, we analyze exons 2-20 in 52 primary UBC and find that all mutant tumors belong to the aggressive UBC phenotype (high grade non-muscle invasive and muscle invasive tumors) (P = 0.05). In a second series (n = 84), we assess ARID1A expression using immunohistochemistry, a surrogate for mutation analysis, and find that loss of expression increases with higher stage/grade, it is inversely associated with FGFR3 overexpression (P = 0.03) but it is not correlated with p53 overexpression (P = 0.30). We also analyzed the expression of cytokeratins in the same set of tumor and find, using unsupervised clustering, that tumors with ARID1A loss of expression are generally KRT5/6-low. In this patient series, loss of ARID1A expression is also associated with worse prognosis, likely reflecting the higher prevalence of losses found in tumors of higher stage and grade. The independent findings in these two sets of patients strongly support the notion that ARID1A inactivation is a key player in bladder carcinogenesis occurring predominantly in FGFR3 wild type tumors.Cristina Balbás-MartínezMaría Rodríguez-PinillaAriel CasanovaOrlando DomínguezDavid G PisanoGonzalo GómezJosep LloretaJosé A LorenteNúria MalatsFrancisco X RealPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 5, p e62483 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Cristina Balbás-Martínez María Rodríguez-Pinilla Ariel Casanova Orlando Domínguez David G Pisano Gonzalo Gómez Josep Lloreta José A Lorente Núria Malats Francisco X Real ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| description |
Urothelial bladder cancer (UBC) is heterogeneous at the clinical, pathological, genetic, and epigenetic levels. Exome sequencing has identified ARID1A as a novel tumor suppressor gene coding for a chromatin remodeling protein that is mutated in UBC. Here, we assess ARID1A alterations in two series of patients with UBC. In the first tumor series, we analyze exons 2-20 in 52 primary UBC and find that all mutant tumors belong to the aggressive UBC phenotype (high grade non-muscle invasive and muscle invasive tumors) (P = 0.05). In a second series (n = 84), we assess ARID1A expression using immunohistochemistry, a surrogate for mutation analysis, and find that loss of expression increases with higher stage/grade, it is inversely associated with FGFR3 overexpression (P = 0.03) but it is not correlated with p53 overexpression (P = 0.30). We also analyzed the expression of cytokeratins in the same set of tumor and find, using unsupervised clustering, that tumors with ARID1A loss of expression are generally KRT5/6-low. In this patient series, loss of ARID1A expression is also associated with worse prognosis, likely reflecting the higher prevalence of losses found in tumors of higher stage and grade. The independent findings in these two sets of patients strongly support the notion that ARID1A inactivation is a key player in bladder carcinogenesis occurring predominantly in FGFR3 wild type tumors. |
| format |
article |
| author |
Cristina Balbás-Martínez María Rodríguez-Pinilla Ariel Casanova Orlando Domínguez David G Pisano Gonzalo Gómez Josep Lloreta José A Lorente Núria Malats Francisco X Real |
| author_facet |
Cristina Balbás-Martínez María Rodríguez-Pinilla Ariel Casanova Orlando Domínguez David G Pisano Gonzalo Gómez Josep Lloreta José A Lorente Núria Malats Francisco X Real |
| author_sort |
Cristina Balbás-Martínez |
| title |
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| title_short |
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| title_full |
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| title_fullStr |
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| title_full_unstemmed |
ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors. |
| title_sort |
arid1a alterations are associated with fgfr3-wild type, poor-prognosis, urothelial bladder tumors. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/b881dfb55ce4481c96fc619a4d0cc19a |
| work_keys_str_mv |
AT cristinabalbasmartinez arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT mariarodriguezpinilla arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT arielcasanova arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT orlandodominguez arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT davidgpisano arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT gonzalogomez arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT joseplloreta arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT josealorente arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT nuriamalats arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors AT franciscoxreal arid1aalterationsareassociatedwithfgfr3wildtypepoorprognosisurothelialbladdertumors |
| _version_ |
1718422996580827136 |